$NVCR

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was f

Novocure (NVCR) reported a cybersecurity incident in mid-August 2026, exposing patient data and employee information. The company stated that medical devices were not accessed and operations remained unaffected. NVCR shares have risen 3.2% since the announcement and 38.8% year-to-date. The company does not expect a material financial impact. The incident is part of a broader trend in the healthcare and medtech industry.

U.S. stock futures mostly rose late Wednesday as traders reacted to a strong January jobs report and a House vote to rescind Trump's Canadian tariffs. VKTX shares jumped 9% after announcing late-stage obesity drug trials. CRM hit a 52-week low amid AI concerns. NVCR surged 30% after FDA approval for a pancreatic cancer treatment. QS rose 10% despite reporting a quarterly loss. Retail investors increased purchases of software stocks, with IGV seeing record activity. The 10-year Treasury yield ros

Novocure, an oncology company, reported a cyberattack in mid-August that exposed records of over 1,400 U.S. patients. The breach included patient ID numbers, contact info, and some additional identifying data for fewer than 50 patients. The company stated that medical devices were unaffected and financial impact is not expected. Novocure has activated its cybersecurity response plan and initiated an investigation.

NovoCure (NVCR) reported Q2 net revenue of $183.58M and a net loss of $15.66M, and raised its 2026 net revenue outlook to $710M–$725M. The company said it received a CE Mark for Optune Pax in locally advanced pancreatic cancer and expects FDA premarket approval for TTFields in brain metastases from NSCLC.

CSX, Union Pacific (UNP), and Novocure (NVCR) reached 52-week highs after Q2 results beat analyst expectations. CSX reported $3.94B revenue and $0.54 EPS vs $3.8B and $0.52, and analysts raised targets. UNP posted $3.41 adjusted EPS and $6.9B revenue vs $3.23 and higher volumes. NVCR shares rose 28% after Q2 revenue rose 15.6% to $183.6M and adjusted EBITDA turned profitable.

NovoCure (NVCR) reported a narrower-than-expected loss of 13 cents per share and revenue up 16% to $183.584 million, above the $172.437 million estimate. It raised fiscal 2026 revenue guidance to $710 million-$725 million. CE Mark received for Optune Pax in pancreatic cancer. Analysts’ targets range from $17 to $52.

H.C. Wainwright cut its NovoCure Ltd. (NASDAQ:NVCR) price target to $32 from $46 but kept a Buy rating. NVCR trades around $19.99. The firm cited NovoCure’s Q2 2026 revenue of $183.6M and updated 2026 revenue guidance to $710M-$725M, with adjusted EBITDA guidance revised to $0-$15M.

Biotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.